Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ticagrelor Combined With ASA Versus ASA Alone in Acute Ischemic Stroke or TIA
NCT04962451Phase 4Completed
- Sponsor
- Peking University Third Hospital
- Start
- Sep 2017
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of ticagrelor in ischemic stroke and Transient Ischemic Attack (TIA) (2 arms), sponsored by Peking University Third Hospital. Primary endpoints: Occurrence of adverse events at Day 60 and Subsequent Stroke or Death at Day 60. Started Sep 2017; status: completed.
02
Drugs
ticagrelor
03
Conditions
ischemic strokeTransient Ischemic Attack (TIA)
Beyond the preview
Go deeper on NCT04962451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04962451.